DGAP-News: Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis
DGAP-News: ABIVAX
/ Key word(s): Study results
Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis
06.04.2022 / 18:00
The issuer is solely responsible for the content of this...